Insmed Incorporated (0JAV.L)
USD 72.71
(0.36%)
USD 72.71
(0.36%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -749.56 Million USD | -55.66% |
| 2022 | -481.53 Million USD | -10.79% |
| 2021 | -434.65 Million USD | -47.8% |
| 2020 | -294.09 Million USD | -15.63% |
| 2019 | -254.33 Million USD | 21.57% |
| 2018 | -324.27 Million USD | -68.33% |
| 2017 | -192.64 Million USD | -9.29% |
| 2016 | -176.27 Million USD | -49.15% |
| 2015 | -118.18 Million USD | -49.3% |
| 2014 | -79.15 Million USD | -41.17% |
| 2013 | -56.07 Million USD | -35.53% |
| 2012 | -41.37 Million USD | 30.66% |
| 2011 | -59.66 Million USD | -827.32% |
| 2010 | -6.43 Million USD | -105.44% |
| 2009 | 118.35 Million USD | 855.41% |
| 2008 | -15.66 Million USD | 21.52% |
| 2007 | -19.96 Million USD | 64.44% |
| 2006 | -56.13 Million USD | -37.16% |
| 2005 | -40.92 Million USD | -50.46% |
| 2004 | -27.2 Million USD | -164.16% |
| 2003 | -10.29 Million USD | 71.72% |
| 2002 | -36.41 Million USD | 2.02% |
| 2001 | -37.16 Million USD | 53.46% |
| 2000 | -79.86 Million USD | -924.83% |
| 1999 | -7.79 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -300.6 Million USD | -91.36% |
| 2024 Q1 | -157.09 Million USD | 15.57% |
| 2024 Q3 | -220.52 Million USD | 26.64% |
| 2023 Q2 | -244.8 Million USD | -53.23% |
| 2023 Q4 | -186.06 Million USD | -17.07% |
| 2023 Q3 | -158.93 Million USD | 35.08% |
| 2023 FY | -749.56 Million USD | -55.66% |
| 2023 Q1 | -159.76 Million USD | 0.22% |
| 2022 Q1 | -94.62 Million USD | 16.25% |
| 2022 FY | -481.53 Million USD | -10.79% |
| 2022 Q4 | -160.12 Million USD | -22.1% |
| 2022 Q3 | -131.14 Million USD | -37.12% |
| 2022 Q2 | -95.64 Million USD | -1.08% |
| 2021 FY | -434.65 Million USD | -47.8% |
| 2021 Q3 | -112.71 Million USD | 3.93% |
| 2021 Q4 | -112.97 Million USD | -0.23% |
| 2021 Q2 | -117.32 Million USD | -28.02% |
| 2021 Q1 | -91.64 Million USD | 10.34% |
| 2020 Q3 | -63.65 Million USD | -2.92% |
| 2020 Q1 | -66.36 Million USD | -25.24% |
| 2020 Q4 | -102.21 Million USD | -60.56% |
| 2020 Q2 | -61.85 Million USD | 6.8% |
| 2020 FY | -294.09 Million USD | -15.63% |
| 2019 Q2 | -66.51 Million USD | 10.3% |
| 2019 Q4 | -52.98 Million USD | 12.68% |
| 2019 FY | -254.33 Million USD | 21.57% |
| 2019 Q3 | -60.68 Million USD | 8.77% |
| 2019 Q1 | -74.15 Million USD | 19.02% |
| 2018 Q2 | -76.43 Million USD | -11.55% |
| 2018 Q1 | -68.52 Million USD | -4.8% |
| 2018 FY | -324.27 Million USD | -68.33% |
| 2018 Q4 | -91.57 Million USD | -4.37% |
| 2018 Q3 | -87.74 Million USD | -14.79% |
| 2017 FY | -192.64 Million USD | -9.29% |
| 2017 Q1 | -37.41 Million USD | 45.3% |
| 2017 Q4 | -65.38 Million USD | -44.72% |
| 2017 Q2 | -44.67 Million USD | -19.4% |
| 2017 Q3 | -45.17 Million USD | -1.13% |
| 2016 Q4 | -68.4 Million USD | -81.15% |
| 2016 Q3 | -37.76 Million USD | -3.23% |
| 2016 FY | -176.27 Million USD | -49.15% |
| 2016 Q1 | -33.53 Million USD | -7.32% |
| 2016 Q2 | -36.57 Million USD | -9.09% |
| 2015 Q3 | -30.96 Million USD | -8.23% |
| 2015 Q1 | -27.36 Million USD | -55.09% |
| 2015 Q4 | -31.24 Million USD | -0.91% |
| 2015 FY | -118.18 Million USD | -49.3% |
| 2015 Q2 | -28.6 Million USD | -4.52% |
| 2014 Q2 | -23.22 Million USD | -62.43% |
| 2014 Q4 | -17.64 Million USD | 26.44% |
| 2014 FY | -79.15 Million USD | -41.17% |
| 2014 Q1 | -14.29 Million USD | 11.82% |
| 2014 Q3 | -23.99 Million USD | -3.3% |
| 2013 Q1 | -13.67 Million USD | 11.47% |
| 2013 FY | -56.07 Million USD | -35.53% |
| 2013 Q4 | -16.21 Million USD | 6.42% |
| 2013 Q3 | -17.32 Million USD | -95.7% |
| 2013 Q2 | -8.85 Million USD | 35.27% |
| 2012 Q2 | -9.69 Million USD | -41.65% |
| 2012 Q1 | -6.84 Million USD | 16.14% |
| 2012 FY | -41.37 Million USD | 30.66% |
| 2012 Q4 | -15.45 Million USD | -64.69% |
| 2012 Q3 | -9.38 Million USD | 3.24% |
| 2011 FY | -59.66 Million USD | -827.32% |
| 2011 Q2 | -10.01 Million USD | -45.3% |
| 2011 Q1 | -6.89 Million USD | -17.97% |
| 2011 Q3 | -34.59 Million USD | -245.32% |
| 2011 Q4 | -8.16 Million USD | 76.4% |
| 2010 Q1 | 118 Thousand USD | -94.88% |
| 2010 Q4 | -5.84 Million USD | -1670.91% |
| 2010 FY | -6.43 Million USD | -105.44% |
| 2010 Q2 | -378 Thousand USD | -420.34% |
| 2010 Q3 | -330 Thousand USD | 12.7% |
| 2009 Q4 | 2.3 Million USD | 1637.33% |
| 2009 FY | 118.35 Million USD | 855.41% |
| 2009 Q2 | -1.6 Million USD | -101.36% |
| 2009 Q1 | 117.79 Million USD | 3071.62% |
| 2009 Q3 | -150 Thousand USD | 90.63% |
| 2008 Q4 | -3.96 Million USD | -83.26% |
| 2008 Q2 | -4.66 Million USD | 4.23% |
| 2008 Q3 | -2.16 Million USD | 53.65% |
| 2008 Q1 | -4.87 Million USD | -47.8% |
| 2008 FY | -15.66 Million USD | 21.52% |
| 2007 Q4 | -3.29 Million USD | 15.72% |
| 2007 Q3 | -3.91 Million USD | -56.48% |
| 2007 Q2 | -2.5 Million USD | 75.62% |
| 2007 Q1 | -10.25 Million USD | 52.15% |
| 2007 FY | -19.96 Million USD | 64.44% |
| 2006 Q3 | -12.37 Million USD | -38.84% |
| 2006 Q2 | -8.91 Million USD | 33.63% |
| 2006 Q1 | -13.42 Million USD | -4.21% |
| 2006 Q4 | -21.42 Million USD | -73.2% |
| 2006 FY | -56.13 Million USD | -37.16% |
| 2005 Q1 | -5.76 Million USD | 1.25% |
| 2005 Q2 | -8.52 Million USD | -47.88% |
| 2005 FY | -40.92 Million USD | -50.46% |
| 2005 Q3 | -13.75 Million USD | -61.38% |
| 2005 Q4 | -12.88 Million USD | 6.33% |
| 2004 Q2 | -9.01 Million USD | -89.35% |
| 2004 Q1 | -4.75 Million USD | -94.17% |
| 2004 FY | -27.2 Million USD | -164.16% |
| 2004 Q3 | -7.59 Million USD | 15.7% |
| 2004 Q4 | -5.83 Million USD | 23.16% |
| 2003 Q1 | -2.2 Million USD | 88.06% |
| 2003 FY | -10.29 Million USD | 71.72% |
| 2003 Q4 | -2.45 Million USD | -2.21% |
| 2003 Q3 | -2.39 Million USD | 25.99% |
| 2003 Q2 | -3.24 Million USD | -46.67% |
| 2002 Q1 | -6.1 Million USD | 38.39% |
| 2002 Q2 | -7.1 Million USD | -16.37% |
| 2002 FY | -36.41 Million USD | 2.02% |
| 2002 Q4 | -18.49 Million USD | -293.05% |
| 2002 Q3 | -4.7 Million USD | 33.78% |
| 2001 FY | -37.16 Million USD | 53.46% |
| 2001 Q4 | -9.91 Million USD | -18.41% |
| 2001 Q3 | -8.37 Million USD | 4.8% |
| 2001 Q2 | -8.79 Million USD | 12.88% |
| 2001 Q1 | -10.09 Million USD | -27.76% |
| 2000 FY | -79.86 Million USD | -924.83% |
| 2000 Q4 | -7.9 Million USD | -53.49% |
| 2000 Q3 | -5.14 Million USD | 90.73% |
| 2000 Q1 | -11.3 Million USD | 0.0% |
| 2000 Q2 | -55.51 Million USD | -391.23% |
| 1999 Q1 | -1.49 Million USD | 0.0% |
| 1999 FY | -7.79 Million USD | 0.0% |
| 1999 Q2 | -1.55 Million USD | -4.5% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -153.21 Million USD | -389.213% |
| Dynavax Technologies Corporation | -6.38 Million USD | -11632.149% |
| Cara Therapeutics, Inc. | -118.51 Million USD | -532.477% |
| Walgreens Boots Alliance, Inc. | -8.63 Billion USD | 91.32% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 57057.979% |
| Perrigo Company plc | -12.7 Million USD | -5802.102% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | -171.458% |
| Illumina, Inc. | -1.16 Billion USD | 35.438% |
| Thermo Fisher Scientific Inc. | 5.99 Billion USD | 112.503% |
| Nektar Therapeutics | -276.05 Million USD | -171.527% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | -68.807% |
| IQVIA Holdings Inc. | 1.35 Billion USD | 155.196% |
| Heron Therapeutics, Inc. | -110.55 Million USD | -577.979% |
| Unity Biotechnology, Inc. | -39.86 Million USD | -1780.499% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | 547.116% |
| Waters Corporation | 642.23 Million USD | 216.712% |
| Biogen Inc. | 1.16 Billion USD | 164.557% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | -190.72% |
| Adicet Bio, Inc. | -142.65 Million USD | -425.429% |
| Evolus, Inc. | -61.68 Million USD | -1115.153% |
| bluebird bio, Inc. | -211.91 Million USD | -253.714% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | -747.15% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | -258.219% |
| FibroGen, Inc. | -284.23 Million USD | -163.717% |
| Agilent Technologies, Inc. | 1.24 Billion USD | 160.449% |
| Homology Medicines, Inc. | -53.74 Million USD | -1294.725% |
| Geron Corporation | -184.12 Million USD | -307.092% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | -70.262% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | -1580.519% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | -394.49% |
| Myriad Genetics, Inc. | -112 Million USD | -569.256% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 118.959% |
| OPKO Health, Inc. | -188.86 Million USD | -296.884% |
| Viking Therapeutics, Inc. | -85.89 Million USD | -772.655% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | -55.773% |
| Zoetis Inc. | 2.34 Billion USD | 131.978% |
| Abeona Therapeutics Inc. | -54.18 Million USD | -1283.271% |
| Mettler-Toledo International Inc. | 788.77 Million USD | 195.029% |
| Exelixis, Inc. | 207.76 Million USD | 460.776% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 120.709% |
| uniQure N.V. | -308.47 Million USD | -142.989% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | -1676.267% |
| Anavex Life Sciences Corp. | -47.5 Million USD | -1477.87% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | -213.314% |
| Verastem, Inc. | -87.36 Million USD | -757.952% |
| Imunon, Inc. | -19.51 Million USD | -3740.983% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | -104.64% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | -39.851% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 400.187% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | 806.206% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 366.187% |
| TG Therapeutics, Inc. | 12.67 Million USD | 6015.144% |
| Blueprint Medicines Corporation | -506.98 Million USD | -47.848% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | -112.892% |
| Incyte Corporation | 597.59 Million USD | 225.43% |
| Emergent BioSolutions Inc. | -760.5 Million USD | 1.438% |